Ignite Creation Date:
2024-05-06 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05863234
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-05-09
Brief Title:
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Sponsor:
Hiroshima University Hospital
Organization:
Hiroshima University Hospital
Study Overview
Official Title:
Multicenter Open-label Dose-escalation Phase III Study to Evaluate the Tolerability Safety Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia ANKL Physician-initiated Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is Phase III Dose-Escalation Study to evaluate the tolerability safety efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None